1.905

2.14% 0.04

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $1.905, with a volume of 1.47M. It is up +2.14% in the last 24 hours and up +29.59% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$1.865

Open:

$1.83

24h Volume:

1.47M

Relative Volume:

1.08

Market Cap:

$206.48M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-1.7009

EPS:

-1.12

Net Cash Flow:

$-120.82M

1W Performance:

+27.00%

1M Performance:

+29.59%

6M Performance:

-51.40%

1Y Performance:

-73.13%

1-Day Range:

$1.79

$2.04

1-Week Range:

$1.47

$3.00

52-Week Range:

$1.03

$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1178)

Industry

Biotechnology (668)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

155

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	1.905	164.76M	42.51M	-116.49M	-120.82M	-1.12
ONC Beigene Ltd Adr	241.93	24.41B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	434.78	111.55B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.31	42.47M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	588.22	63.16B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.03	5.92B	0	-153.72M	-103.81M	-2.00

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

May 22, 2025

Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance

May 22, 2025

May 21, 2025

Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa

May 21, 2025

Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com

May 21, 2025

TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus

May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire

May 21, 2025

Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan

May 21, 2025

May 18, 2025

Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World

May 18, 2025

May 16, 2025

Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World

May 16, 2025

May 15, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

May 15, 2025

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st

May 15, 2025

Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 15, 2025